Anti-MPXV M1R (Clone: MPXV-26) – Purified No Carrier Protein

MPXV-26 was generated from peripheral blood mononuclear cells obtained from donors who had recovered from naturally-occurring MPXV infection⁵.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.

Standard Overnight on Blue Ice.

ELISA
N

Anti-MPXV M1R (clone name: MPXV-26) is reactive against the MV membrane protein encoded by ORF M1R of monkeypox virus (Homologous to Vaccinia virus L1R). Complementary screening approaches were used to identify orthopoxvirus-specific mAbs to MPXV, cowpox virus (CPXV), variola virus (VARV), and vaccinia virus (VACV). MPXV-26 is reactive to VACV antigen, CPXV lysate, VARV antigen and lysate, but not MPXV lysate. MPXV-26 binds to VACV and VARV purified antigens and CPXV virus-infected cell lysate but not VACV and MPXV cell lysates.

MPXV-26 neutralizes VACV MV and MV plus complement (MV+C’) and weakly neutralizes MPXV MV and MV+C’.

When MPXV-26 is mixed with other mAbs, neutralization and cross-neutralization are more efficient than in individual assays⁵. These mAb mixes also provide protection against VACV in mice. While not completely protective on its own, MPXV-26 induces delayed morbidity and mortality in mice, and mixes that exclude MPXV-26 are less effective prophylactics.

Monkeypox virus (MPXV) is a zoonotic member of the Orthopoxvirus genus in the Poxviridae family¹. It is the next most pathogenic poxvirus after smallpox. Two genetic clades, West African and Central African (Congo Basin), have been characterized; the latter is capable of human-to-human transmission^1,2. Monkeypox has gained clinical relevance due to the eradication of smallpox, which has created opportunities for increased prevalence and viral mutations that may affect virulence^{1, 2}. An infection with one orthopoxvirus of any one species, or vaccinia virus vaccination, protects against infection by other orthopoxviruses^3,4,5. MPXV is an enveloped virus with a linear, double-stranded DNA genome² and a large, complex proteome of over 200 proteins⁶. During infection, the virus exists in two antigenically distinct forms: mature virions (MV) or enveloped virions (EV)⁶.

L1 is a mature virion surface protein.

1. Sklenovská N, Van Ranst M. Front Public Health. 6:241. 2018.
2. Moore M, Zahra F. 2021 Oct 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
3. McConnell S, Herman YF, Mattson DE, et al. Am J Vet Res. 25:192-195. 1964.
4. Hammarlund E, Lewis MW, Carter SV, et al. Nat Med. 11(9):1005-1011. 2005.
5. Gilchuk I, Gilchuk P, Sapparapu G, et al. Cell. 167(3):684-694.e9. 2016.
6. Moss B. Immunol Rev.239:8–26. 2011.